Renaissance of amantadine in the treatment of Parkinson's disease
- Author
- BLANCHET, Pierre J1 2 ; VERHAGEN METMAN, Leo1 3 ; CHASE, Thomas N1
[1] Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, United States
[2] Faculty of Dentistry, University of Montreal, Montreal, Quebec, Canada
[3] Department of Neurology, Rush-Presbytarian-St. Luke ' s Medical Center, Chicago, Illinois, United States - Issue title
- Parkinson's Disease
- Author (monograph)
- GORDIN, Ariel (Editor)1 ; KAAKKOLA, Seppo (Editor)2 ; TERÄVÄINEN, Heikki (Editor)2
[1] Research Centre, Orion Pharma, Orionintie 1, 02100 Espoo, Finland
[2] Department of Neurology, University of Helsinki, Helsinki, Finland - Source
Advances in neurology. 2003, Vol 91, pp 251-257, 7 p ; ref : 44 ref
- Publisher
- Lippincott - Raven, New York, NY
/
Lippincott - Raven, Philadelphia, PA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Agoniste Amantadine Antagoniste Antiparkinsonien Chimiothérapie Homme Parkinson maladie Récepteur NMDA Récepteur dopaminergique Récepteur glutamate Stimulant dopaminergique Traitement Encéphale pathologie Extrapyramidal syndrome Maladie dégénérative Système nerveux central pathologie Système nerveux pathologie
- Keyword (en)
- Agonist Amantadine Antagonist Antiparkinson agent Chemotherapy Human Parkinson disease NMDA receptor Dopamine receptor Glutamate receptor Dopamine agonist Treatment Cerebral disorder Extrapyramidal syndrome Degenerative disease Central nervous system disease Nervous system diseases
- Keyword (es)
- Agonista Amantadina Antagonista Antiparkinsoniano Quimioterapia Hombre Parkinson enfermedad Receptor NMDA Receptor dopaminérgico Receptor glutámato Estimulante dopaminérgico Tratamiento Encéfalo patología Extrapiramidal síndrome Enfermedad degenerativa Sistema nervosio central patología Sistema nervioso patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02B Neuropharmacology / 002B02B06 Anticonvulsants. Antiepileptics. Antiparkinson agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B17 Neurology / 002B17G Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
- Discipline
- Neurology Pharmacological treatments Psychopathology. Psychiatry. Clinical psychology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 14986416
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:65:\"Renaissance of amantadine in the treatment of Parkinson's disease\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Advances in neurology\";s:9:\"\u0000*\u0000stitle\";s:11:\"Adv. neurol\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"91\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"251\";s:8:\"\u0000*\u0000epage\";s:3:\"257\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0091-3952\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"BLANCHET\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Pierre J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:20:\"VERHAGEN METMAN, Leo\";i:1;s:15:\"CHASE, Thomas N\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ADNRA3\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:19:\"Parkinson's Disease\";s:8:\"\u0000*\u0000title\";s:65:\"Renaissance of amantadine in the treatment of Parkinson's disease\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:18:\"Lippincott - Raven\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:65:\"Renaissance of amantadine in the treatment of Parkinson's disease\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Advances in neurology\";s:9:\"\u0000*\u0000stitle\";s:11:\"Adv. neurol\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"91\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"251\";s:8:\"\u0000*\u0000epage\";s:3:\"257\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0091-3952\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"BLANCHET\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Pierre J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:20:\"VERHAGEN METMAN, Leo\";i:1;s:15:\"CHASE, Thomas N\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ADNRA3\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:19:\"Parkinson's Disease\";s:8:\"\u0000*\u0000title\";s:65:\"Renaissance of amantadine in the treatment of Parkinson's disease\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:18:\"Lippincott - Raven\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:65:\"Renaissance of amantadine in the treatment of Parkinson's disease\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Advances in neurology\";s:9:\"\u0000*\u0000stitle\";s:11:\"Adv. neurol\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"91\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"251\";s:8:\"\u0000*\u0000epage\";s:3:\"257\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0091-3952\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"BLANCHET\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Pierre J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:20:\"VERHAGEN METMAN, Leo\";i:1;s:15:\"CHASE, Thomas N\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ADNRA3\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:19:\"Parkinson's Disease\";s:8:\"\u0000*\u0000title\";s:65:\"Renaissance of amantadine in the treatment of Parkinson's disease\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:18:\"Lippincott - Raven\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:65:\"Renaissance of amantadine in the treatment of Parkinson's disease\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Advances in neurology\";s:9:\"\u0000*\u0000stitle\";s:11:\"Adv. neurol\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"91\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"251\";s:8:\"\u0000*\u0000epage\";s:3:\"257\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0091-3952\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"BLANCHET\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Pierre J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:20:\"VERHAGEN METMAN, Leo\";i:1;s:15:\"CHASE, Thomas N\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ADNRA3\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:19:\"Parkinson's Disease\";s:8:\"\u0000*\u0000title\";s:65:\"Renaissance of amantadine in the treatment of Parkinson's disease\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:18:\"Lippincott - Raven\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:65:\"Renaissance of amantadine in the treatment of Parkinson's disease\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Advances in neurology\";s:9:\"\u0000*\u0000stitle\";s:11:\"Adv. neurol\";s:7:\"\u0000*\u0000date\";s:4:\"2003\";s:9:\"\u0000*\u0000volume\";s:2:\"91\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:3:\"251\";s:8:\"\u0000*\u0000epage\";s:3:\"257\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0091-3952\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"BLANCHET\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Pierre J\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:20:\"VERHAGEN METMAN, Leo\";i:1;s:15:\"CHASE, Thomas N\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"ADNRA3\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:19:\"Parkinson's Disease\";s:8:\"\u0000*\u0000title\";s:65:\"Renaissance of amantadine in the treatment of Parkinson's disease\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:18:\"Lippincott - Raven\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"7\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
